[1] Moore JP,Doms RW.The entry of inhibitors:a fusion of science and medicine[J].Proc Natl Acad Sci U S A,2003,100(19):10598-10602.
[2] Weber KS,Grone HJ,Rocken M,et al.Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-Ⅱ[J].Eur J Immunol,2001,31(8):2458-2466.
[3] Li Y,Liu D,Cao R,et al.Crystal structure of chemically synthesized vMIP-Ⅱ[J].Proteins,2007,67(1):243-246.
[4] Fernandez EJ,Wilken J,Thompson DA,et al.Comparison of the structure of vMIP-Ⅱ with eotaxin-1,RANTES,and MCP-3 suggests a unique mechanism for CCR3 activation[J].Biochemistry,2000,39(42):12837-12844.
[5] Shao W,Fernandez E,Sachpatzidis A,et al.CCR2 and CCR5 receptor-binding properties of herpesvirus-8 vMIP-Ⅱ based on sequence analysis and its solution structure[J].Eur J Biochem,2001,268(10):2948-2959.
[6] 叶石敦,莫雪梅,张光,等.vMIP-II 各受体结合活性位点分析[J].中国现代医学杂志,2006,16(23):3546-3552.
[7] Zhao B,Liwang PJ.Characterization of the interactions of vMIP-Ⅱ,and a dimeric variant of vMIP-Ⅱ,with glycosaminoglycans[J].Biochemistry,2010,49(33):7012-7022.
[8] Khan A,Greenman J,Archibald SJ.Small molecule CXCR4 chemokine receptor antagonists:developing drug candidates[J].Curr Med Chem,2007,14(21):2257-2277.
[9] 杨清玲,丁勇兴.vMIP 对细胞膜上趋化因子受体亲和力的结合特性研究[J].上海交通大学学报:医学版,2006,26(4):389-392.
[10] Zhou N,Luo Z,Luo J,et al.A novel peptide antagonist of CXCR4 derived from the n-terminus of viral chemokine vMIP-Ⅱ[J].Biochemistry,2000,39(13):3782-3787.
[11] 杨清玲,丁勇兴,张玉心.病毒巨噬细胞炎性蛋白与趋化因子受体结合的效应研究[J].蚌埠医学院学报,2006,31(3):226-229.
[12] Yang QL,Ding YX,Chen CJ,et al.Suppression of murine breast cancer metastasis by selective inhibition of CXCR4 by synthetic polypeptide derived from viral macrophage inflammatory protein II[J].Chinese Sci Bull,2010,20(55):2152-2159.
[13] 杨清玲,杨志峰,高艳军,等.vMIP-Ⅱ N端重组肽的表达纯化及活性鉴定[J].中国生物工程杂志,2010,30(9):80-86.
[14] Wang HK,Park UJ,Kim SY,et al.Free radical production in CA1 neurons induces MIP-1alpha expression,microglia recruitment,and delayed neuronal death after transient forebrain ischemia[J].J Neurosci,2008,28(7):1721-1727.
[15] Minami M,Satoh M.Chemokines and their receptors in the brain:pathophysiological roles in ischemic brain injury[J].Life Sci,2003,74(2/3):321-327.
[16] Cherqui S,Kingdon KM,Thorpe C,et al.Lentiviral gene delivery of vMIP-Ⅱ to transplanted endothelial cells and endothelial progenitors is proangiogenic in vivo[J].Mol Ther,2007,15(7):1264-1272.
[17] Rubant S,Ludwig RJ,Pfeffer J,et al.Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-Ⅱ and its effects on T-cell function in vitro and in vivo[J].Exp Dermatol,2006,15(8):634-642.
[18] Chen S,Bacon KB,Li L,et al.In vitro inhibition of CC andCX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto(WKY) rats by vMIP-Ⅱ[J].J Exp Med,1998,188(1):193.
[19] De Vries ME,Ran L,Kelvin DJ.On the edge:the physiological and pathophysiological role of chemokines during inflammatory and immunological responses[J].Semin Immunol,1999,11(2):95-104.
[20] De Bruyne LA,Li K,Bishop DK,et al.Gene transfer of virally encoded chemokine antagonists vMIP-Ⅱ and MC148 prolongs cardiac allograft survival and inhibits donor-specificimmunity[J].Gene Ther,2000,7(7):575-582.
[21] Bedke J,Stojanovic T,Kiss E,et al.Viral macrophage inflammatory protein-Ⅱ improves acute rejection in allogeneic rat kidney transplants[J].World J Urol,2010,28(4):537-542.
[22] Pillai RG,Beutelspacher SC,Larkin DFP,et al.Expression of the chemokine antagonist vMIP-Ⅱ using a non-viral vector can prolong corneal allograft survival[J].Tranplantation,2008,85(11):1640-1647.
[23] 郑红,苏青和,孙志成,等.重组趋化因子vMIP-Ⅱ对小鼠异体移植皮肤存活时间的影响[J].第三军医大学学报,2002,24(9):1013-1016.
[24] Egorova A,Kiselev A,Hakli M,et al.Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells[J].J Gene Med,2009,11(9):772-781.
[25] Nakano K,Katano H,Tadagaki K,et al.Novel monoclonal antibodies for identification of multicentric Castleman's disease;Kaposi's sarcoma- associated herpesvirus-encoded vMIP-I and vMIP-Ⅱ[J].Virology,2012,425(2):95-102.